

NEUROLOGY INFUSION REFERRAL FORM

PHONE 855.896.9254 | FAX 855.370.0086



Remove above portion before faxing. Please complete the prescription form in its entirety and fax with secure cover sheet to the number above.

PATIENT INFORMATION					
Last Name	First Name	DOB	Gender <input type="checkbox"/> M <input type="checkbox"/> F	Last 4 SSN	Primary Language
Address		City		State	ZIP
Email		Home Phone	Work Phone		Cell Phone
Primary Contact Method (check one) <input type="checkbox"/> Cell Phone <input type="checkbox"/> Home Phone <input type="checkbox"/> Work Phone <input type="checkbox"/> Text <input type="checkbox"/> Email <input type="checkbox"/> Primary Caregiver <input type="checkbox"/> DO NOT CONTACT					
Primary Caregiver/Alt Contact Name (If applicable)			Alt Contact Email		Alt Contact Phone

PRESCRIBER INFORMATION			
Name of Contact Sending Referral		Title	Preferred Contact Method (check one) <input type="checkbox"/> Email <input type="checkbox"/> Phone <input type="checkbox"/> Fax
Referral Contact Email		Office Phone	Office Fax
Practice / Facility Name		Prescriber Name / Specialty	
Address		City	State ZIP

** Please include a copy of the front and back of insurance card **

CLINICAL INFORMATION - Please include applicable clinical chart notes				
Patient New to Therapy <input type="checkbox"/> Naïve/New Start <input type="checkbox"/> Therapy Restart <input type="checkbox"/> Existing Treatment <input type="checkbox"/>				Therapy Start Date
Sample/Starter Provided? <input type="checkbox"/> No <input type="checkbox"/> Yes, Provide Qty:	Date Provided:	Patient Height (cm/in):	Weight (kg/lbs):	Date Obtained:
Therapies Tried and Failed (please list medications)				
Other/Concomitant Medications (please list)				
Allergies <input type="checkbox"/> NKDA <input type="checkbox"/> Drug Allergies (please list)				
Ship to Address <input type="checkbox"/> Home <input type="checkbox"/> Prescriber's Office <input type="checkbox"/> Other (please list)				
ICD-10 Code <input type="checkbox"/> D69.3 Immune Thrombocytopenic Purpura <input type="checkbox"/> G70.00 Myasthenia Gravis without (acute) exacerbation <input type="checkbox"/> G25.82 Stiff-man Syndrome <input type="checkbox"/> G70.01 Myasthenia Gravis with (acute) exacerbation <input type="checkbox"/> G35 Multiple Sclerosis <input type="checkbox"/> L10.0 Pemphigus Vulgaris <input type="checkbox"/> G60.3 Idiopathic Progressive Neuropathy <input type="checkbox"/> M33.20 Polymyositis organ involvement unspecified <input type="checkbox"/> G61.0 Guillain-Barre Syndrome <input type="checkbox"/> M33.90 Dermatopolymyositis organ involvement unspecified <input type="checkbox"/> G61.81 Chronic Inflammatory Demyelinating Polyneuritis <input type="checkbox"/> Other _____ <input type="checkbox"/> G62.89 Multifocal Motor Neuropathy				

PRESCRIPTION INFORMATION - Please Escribe if required by state law
 In order for a brand name product to be dispensed, the prescriber must handwrite "Brand Necessary" or "Brand Medically Necessary," or your state-specific required language to prohibit substitutions. This form is not a valid prescription form for writing controlled medications.

MEDICATION	ROUTE	DOSE/STRENGTH	DIRECTIONS	QTY	REFILLS
<input type="checkbox"/> Briumvi	<input type="checkbox"/> IV	<input type="checkbox"/> 150 mg	<input type="checkbox"/> Starting Dose - 150 mg on day 1, followed by 450 mg once 2 weeks later <input type="checkbox"/> Maintenance Dose - 450 mg once every 24	3 Vials	0
<input type="checkbox"/> Immune Globulin	<input type="checkbox"/> SC <input type="checkbox"/> IV <input type="checkbox"/> IM	<input type="checkbox"/> _____ grams <input type="checkbox"/> _____ grams	<input type="checkbox"/> 1 mg/kg/hr for first 30 minutes then increase every 30 minutes to a max rate of 6m/kg/hr not to exceed 300 ml/hr	<input type="checkbox"/> 1 month <input type="checkbox"/> 3 months <input type="checkbox"/> _____	<input type="checkbox"/> 1 year <input type="checkbox"/> _____
<input type="checkbox"/> Lemtrada	<input type="checkbox"/> IV	<input type="checkbox"/> 12 mg/day	<input type="checkbox"/> Initial Dose - 12 mg/day over 4 hours for 5 consecutive days <input type="checkbox"/> Maintenance Dose - 12 mg/day IV over 4 hours for 3 consecutive dates 12 months after initial dose		<input type="checkbox"/> 1 year <input type="checkbox"/> _____
<input type="checkbox"/> Ocrevus	<input type="checkbox"/> IV	<input type="checkbox"/> 300 mg/10 mL vial	<input type="checkbox"/> Starter Dose - Infuse 300 mg iv over no less than 2.5 hours on day 1 and day 15 <input type="checkbox"/> Maintenance Dose - Infuse 600 mg iv over no less than 3.5 hours every 6 months		<input type="checkbox"/> 1 year <input type="checkbox"/> _____
<input type="checkbox"/> Vascular Access Method <input type="checkbox"/> peripheral <input type="checkbox"/> central <input type="checkbox"/> other: _____					
<input type="checkbox"/> Normal Saline <input type="checkbox"/> D5W	<input type="checkbox"/> IV	<input type="checkbox"/> 3 mL <input type="checkbox"/> 5 mL <input type="checkbox"/> _____	<input type="checkbox"/> Before and after infusion <input type="checkbox"/> _____	<input type="checkbox"/> 1 month <input type="checkbox"/> 3 months <input type="checkbox"/> _____	<input type="checkbox"/> 1 year <input type="checkbox"/> _____
<input type="checkbox"/> Heparin 10 units/mL <input type="checkbox"/> Heparin 100 units/mL	<input type="checkbox"/> IV	<input type="checkbox"/> 3 mL <input type="checkbox"/> 5 mL <input type="checkbox"/> _____	<input type="checkbox"/> After infusion <input type="checkbox"/> _____	<input type="checkbox"/> 1 month <input type="checkbox"/> 3 months <input type="checkbox"/> _____	<input type="checkbox"/> 1 year <input type="checkbox"/> _____
<input type="checkbox"/> Diphenhydramine	<input type="checkbox"/> PO <input type="checkbox"/> IV <input type="checkbox"/> IM	<input type="checkbox"/> 25 mg <input type="checkbox"/> 50 mg <input type="checkbox"/> _____	<input type="checkbox"/> After infusion <input type="checkbox"/> PRN Allergic Reaction: _____ <input type="checkbox"/> _____	<input type="checkbox"/> With each infusion <input type="checkbox"/> _____	<input type="checkbox"/> 1 year <input type="checkbox"/> _____
<input type="checkbox"/> Acetaminophen	<input type="checkbox"/> PO	<input type="checkbox"/> 325 mg <input type="checkbox"/> 500 mg <input type="checkbox"/> 650 mg <input type="checkbox"/> 1 gm <input type="checkbox"/> _____	<input type="checkbox"/> Pre-Med: _____ <input type="checkbox"/> _____	<input type="checkbox"/> With each infusion <input type="checkbox"/> _____	<input type="checkbox"/> 1 year <input type="checkbox"/> _____
<input type="checkbox"/> Epinephrine	<input type="checkbox"/> IM <input type="checkbox"/> SQ	<input type="checkbox"/> Adult 1:1000, 0.3 mL (>30kg/>66lbs) <input type="checkbox"/> Peds 1:2000, 0.3 mL (15-30kg/33-66lbs)	<input type="checkbox"/> PRN Anaphylaxis <input type="checkbox"/> Repeating Dose: _____	<input type="checkbox"/> Once <input type="checkbox"/> _____	<input type="checkbox"/> 1 year <input type="checkbox"/> _____
<input type="checkbox"/> Other:	<input type="checkbox"/> _____				

Prescriber Signature	Date	Supervising Physician Signature (where required by state law)	NPI #	Date
DAW (Dispense as Written)	Date	Brand Necessary (must handwrite)		

Note: The information contained in this document will become a legal prescription. Prescriber is to comply with his/her state specific Pharmacy and Medical Board guidelines such as e-prescribing, state specific prescription form, fax language, number of prescriptions allowed on a single prescription form, etc. If more than one page is required, make additional copies. Non-compliance with state specific requirements could result in outreach to the prescriber.

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material.